FATİH SAKİN, ERSOY BAYDAR, KADİR SERVİ, AHMET ATEŞŞAHİN, GÜRDAL DAĞOĞLU

İsviçre Esmeri, Holştayn, Simental ve Doğu Anadolu Kırmızısı ırkı ineklerde prob ilaç olarak debrizokin kullanılarak in vivo CYP2D6 enzim aktivitesinin fenotipik belirlenmesi

Mevcut araştırma; İsviçre Esmeri (İE), Holştayn (HOL), Simental (Sİ) ve Doğu Anadolu Kırmızısı (DAK) ırkı ineklerde prob ilaç olarak debrizokin (DEB) kullanılarak sitokrom P450 2D6 (CYP2D6) enzim aktivitesinin fenotipik belirlenmesi amacıyla yapıldı. Çalışmada her ırktan 15 adet olacak şekilde toplam 60 adet inek kullanıldı. İneklere DEB, 0.5 mg/kg dozunda uygulandı. Uygulamayı takiben 12 ve 24. saatlere kadar çıkarılan idrar örnekleri toplandı. İdrar örneklerinde DEB metabolik oranları (DMO) ve DEB rekoveri oranları (DRO) hesaplandı. 12. saat DMO değerleri DAK ırkı ineklerde diğer ırklara göre anlamlı şekilde yüksek olarak bulunurken (P

Anahtar Kelimeler:

idrar analizi, Doğu Anadolu Kırmızısı, Alacalı Sığır, Simmental, İsviçre Esmeri, ırk farklılıkları, sığır, sığır ırkları, inek, süt sığırı, süt ineği, ilaç metabolizması, enzim aktivitesi, enzimler, farmakodinamik, farmakokinetik, farmakoloji, fenotip

Phenotyping determination of in vivo CYP2D6 enzyme activity used as a probe debrisoquine in Swiss Black, Holstein, Simmental and eastern anatolian red cow breeds

In the current study was carried out to determine phenotyping of in vivo CYP2D6 enzyme activity used as a probe debrisoquine (DEB) in Swiss Black (SB), Holstein (HOL), Simmental (SI) and Eastern Anatolian Red (EAR) cows. In the study, totally 60 cows, fifteen cows from each breed, were used. DEB was application at 0.5 mg/kg. Urine samples were collected throughout 12. and 24th h after DEB application. The metabolic (DMR) and recovery (DRR) rates of DEB in urine samples were calculated to evaluate the in vivo activity of CYP2D6 enzyme activity. The DMR value of EAR at 12th h were significantly higher than those others (P<0.01) while this value significantly lower in EAR compared to that of others (P<0.01). The phenotyping CYP2D6 enzyme activity of EAR at 12th h was considered as poor metaboliser (PM) while this phenotype was extensive metabolizer (EM) in SB, HOL and SI cows. In conclusion, it can be considered that urine samples taken at 12th h after DEB administration at dose of 0.5 mg/kg as probe can be used to determine in vivo phenotyping of CYP2D6 enzyme activity in cows. Besides, in implementation of treatment with drugs that are substrates of CYP2D6 in cows, it can be concluded that these drugs will be metabolized more slowly, and the duration time of body and effect durations of action will be increased in EAR cows.

Keywords:

urine analysis, East Anatolian Red, Holstein-Friesian, Simmental, Swiss Black Pied, breed differences, cattle, cattle breeds, cows, dairy cattle, dairy cows, drug metabolism, enzyme activity, enzymes, pharmacodynamics, pharmacokinetics, pharmacology, phenotypes,

PDF

___

1. Mate ML, Lifschitz A, Sallovitz J, Ballent M, Muscher AS, Wilkens MR, Schröder B, Lanusse C, Virkel G: Cytochrome P450 3A expression and function in liver and intestinal mucosa from dexamethasone treated sheep. J Vet Pharmacol Therap, 35, 319-328, 2011.
2. Felmlee MA, Lon HK, Gonzalez FJ, Yu A: Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36, 435-441, 2008.
3. Fink-Gremmels J: Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Pharmacol 585, 502-509, 2008.
4. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, and Battu SK: Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. Johns wort, and Echinacea. Mol Nutr Food Res 52, 755-763, 2008.
5. Szotakova B, Baliharova V, Lamka J, Nozinova E, Wsol V, Velik J, Machala M, Neca J, Soucek P, Susova S, Skalova L: Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci, 76, 43-51, 2004.
6. Yu AM, Idle JR, Gonzalez FJ: Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metab Rev, 36, 243-277, 2004.
7. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J, 5, 6-13,2005.
8. Rendic S: Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev, 34, 83-448, 2002.
9. Jiang XL, Shen HW, Yu AM: Pinoline may be used as a probe for CYP2D6 activity. Drug metabolism and disposition. Drug Metab Dispos, 37, 443-446, 2009.
10. Frank D, Jaehde U, Fuhr U: Evaluation of probe drugs and pharmacokinetic metric for CYP2D6 phenotyping. Eur J Clin Pharmacol, 63, 321-333, 2007.
11. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol, 369, 23-37, 2004.
12. Li Q, Wang R, Guo Y, Wen S, Xu L, Wang S: Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. J Clin Pharm Ther, 35, 239-247, 2010.
13. Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T, Zendulka O: Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther, 37, 486-490, 2012.
14. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance Part I. Clin Pharmacokinet, 48, 689-723, 2009.
15. Eiermann B, Edlund PO, Tjernberg A, Dalen P, Dahl ML, Bertilsson L: 1- and 3- hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos, 26, 1096-1101, 1998.
16. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586, 1977.
17. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci, 90, 11825-11829, 1993.
18. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet, 29, 192-209, 1995.
19. Pereira VA, Auler JO, Carmona MJ, Mateus FH, Lanchote VL, Breimer DD, Santos SR: A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography, Braz J Med Biol Res, 33, 509-514, 2000.
20. Ergün G, Aktaş S: ANOVA modellerinde kareler toplamı yöntemlerinin karşılaştırılması. Kafkas Univ Vet Fak Derg, 15 (3): 481-484, 2009.
21. Streetman DS, Bertino JS and Nafziger AN: Phenotyping of drug metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10, 187-216, 2000.
22. Saadatmand AR, Tadjerpisheh S, Brockmöller J, Tzvetkov MV: The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol, 83, 1427-1434, 2012.
23. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ: The human debrisoquine 4 hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet, 45, 889-904, 1989.
24. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA: Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem, 265, 17209-17214, 1990.
25. LLerena A, Dorado P, Peñas-Lledó EM: Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10, 17-28, 2009.
26. Tucker GT, Houston JB, Huang SM: Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br J Clin Pharmacol, 52, 107-117, 2001.
27. Moffat AC, Osselton MD, Widdop B: Clarkes Analysis of Drugs and Poisons. Vol. 2, 3rd ed., Pharmaceutical Press, London, 2004.
28. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille N, Turgeon J, Hamelin B: Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratio of marker substrates. Pharmacogenetics, 10, 425-438, 2000.
29. Özdemir M, Crewe KH, Tucker GT, Rostami-Hodjean A: Assessment of in vivo CYP2D6 activity: Differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol, 44, 1398-1404, 2004.
30. Jann MW, Cohen LJ: The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact, 16, 39-67, 2001.
31. Meyer UA: Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet, 5, 669-676, 2004.
32. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genoms, 17, 93-101, 2007.
33. Huber-Wechselberger AE, Niedetzky P, Aigner I, Haschke-Becher E: Impact of CYP2D6 polymorphism on tamoxifen therapy: Where are we? Wien Med Wochenschr 162, 252-261, 2012.